Blinatumomab - Emerging Insight and Market Forecast - 2030

This report provides comprehensive insights about an investigational product for Diffuse large B-cell lymphoma (DLBCL) in 7 Major Markets. A detailed picture of the BLINATUMOMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview

Blinatumomab is an investigational BiTE antibody construct designed to direct the body's cell-destroying T cells against target cells expressing CD19, a protein found on the surface of B-cell derived leukemias and lymphomas. Blinatumomab is the first of the BiTE antibody constructs and Amgen has received orphan drug designation from the FDA for the treatment of ALL, chronic lymphocytic leukemia (CLL), hairy cell leukemia, prolymphocytic leukemia and indolent B-cell lymphoma and from the European Medicines Agency for the treatment of indolent B-cell lymphoma, ALL, CLL and mantle cell leukemia (MCL). Blinatumomab is also being investigated for its potential to treat pediatric relapsed/refractory ALL, relapsed/refractory Philadelphia positive (Ph+) B-precursor ALL, minimal residual disease positive (MRD+) B-precursor ALL, relapsed/refractory non-Hodgkin's lymphoma (NHL), including relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around BLINATUMOMAB.
• The report contains forecasted sales for BLINATUMOMAB till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) for Diffuse large B-cell lymphoma (DLBCL).
• The report also features the SWOT analysis with analyst insights and key findings of BLINATUMOMAB.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BLINATUMOMAB Analytical Perspective

In-depth BLINATUMOMAB Market Assessment

This report provides a detailed market assessment of BLINATUMOMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

BLINATUMOMAB Clinical Assessment

The report provides the clinical trials information of BLINATUMOMAB covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Diffuse large B-cell lymphoma (DLBCL) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence BLINATUMOMAB dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Diffuse large B-cell lymphoma (DLBCL) are giving market competition to BLINATUMOMAB and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of BLINATUMOMAB.
• the in-depth analysis of the forecasted sales data of BLINATUMOMAB from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BLINATUMOMAB.

Key Questions Answered

• Which company is developing BLINATUMOMAB along with the phase of the clinical study?
• What is the technology utilized in the development of BLINATUMOMAB?
• What is the product type, route of administration and mechanism of action of BLINATUMOMAB?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BLINATUMOMAB development?
• What are the key designations that have been granted to BLINATUMOMAB?
• What is the forecasted market scenario of BLINATUMOMAB?
• What is the history of BLINATUMOMAB and what is its future?
• What is the forecasted sales of BLINATUMOMAB in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to BLINATUMOMAB?
• Which are the late-stage emerging therapies under development for the treatment of the Diffuse large B-cell lymphoma (DLBCL)?